Publicaciones científicas

del Centro de Investigaciones Oncológicas
  • Evaluation of T-Cell Responses Against Shared Melanoma Associated Antigens and Predicted Neoantigens in Cutaneous Melanoma Patients Treated With the CSF-470 Allogeneic Cell Vaccine Plus BCG and GM-CSF
    Enrique Podaza, Ibel Carri, Mariana Aris, Erika von Euw, Alicia Inés Bravo, Paula Blanco, Juan Manuel Ortiz Wilczyñski, Daniel Koile, Patricio Yankilevich, Morten Nielsen, José Mordoh, María Marcela Barrio. Front Immunol. 2020; 11: 1147. Published online 2020 Jun 5. doi: 10.3389/fimmu.2020.01147
  • Epigenetic inhibitors eliminate senescent melanoma BRAFV600E cells that survive long‑term BRAF inhibition. MadorskyRowdo FP, Barón A, Gallagher SJ, Hersey P, Emran AA, Von Euw EM, Barrio MM, Mordoh J. Int J Oncol. 2020 Jun;56(6):1429-1441. doi: 10.3892/ijo.2020.5031. Epub 2020 Mar 30.
  • Cetuximab and IL-15 Promote NK and Dendritic Cell Activation In Vitro in Triple Negative Breast Cancer. Estefanía Paula Juliá, José Mordoh, Estrella Mariel Levy. Cells. 2020 Jul; 9(7): 1573. Published online 2020 Jun 28. doi: 10.3390/cells9071573
  • Programme for Harmonization to the International Scale in Latin America for BCR-ABL1 quantification in CML patients: findings and recommendations. María Sol Ruiza, María Belén Sáncheza, Yuly Masiel Vera Contreras, Evangelina Agrielo, Marta Alonso, María Eugenia Altuna, María Sol Anchordoqui, Mariana Asinari, María Elisa Bonetto, Mauricio Camargo, Isabel Giere, Javier González, Ana Cecilia Granda Alacote, Javier Guerra, Marina Gutiérrez, Cecilia Maldonado, Ricardo Makiya, Gonzalo Manrique, María Eugenia Monaco, Juan Carlos Rozo, Carlos Santamaría, Analía Seravalle, Olga Zea, María Noel Zubillaga, José Mordoh, Irene Larripa and Michele Bianchini. Clin Chem Lab Med 2020;
  • Peripheral changes in immune cell populations and soluble mediators after anti-PD-1 therapy in non-small cell lung cancer and renal cell carcinoma patients. Juliá EP, Mandó P, Rizzo MM, Cueto GR, Tsou F, Luca R, Pupareli C, Bravo AI, Astorino W, Mordoh J, Martín C, Levy EM. Cancer Immunology Immunotherapy.
  • Immunization With the CSF-470 Vaccine Plus BCG and rhGM-CSF Induced in a Cutaneous Melanoma Patient a TCRβ Repertoire Found at Vaccination Site and Tumor Infiltrating Lymphocytes That Persisted in Blood”. Aris M, Bravo AI, GarciaAlvarez HM, Carri I, Podaza E, Blanco PA, Rotondaro C, Bentivegna S, Nielsen M, Barrio MM and Mordoh J. (2019) Front. Immunol. 10:2213. doi: 10.3389/fimmu.2019.02213
  • Dissecting the immune stimulation promoted by CSF-470 vaccine plus adjuvants in cutaneous melanoma patients: long-term antitumor immunity and short term release of acute inflammatory reactants. Pampena MB; Cartar H; Cueto G; Levy EM, Blanco PA, Barrio MM and Mordoh J. Front Immunol. 2018 Nov 2;9:2531. doi: 10.3389/fimmu.2018.02531. eCollection 2018.
  • Avelumab, an IgG1 anti-PD-L1 Immune Checkpoint Inhibitor, Triggers NK Cell-Mediated Cytotoxicity and Cytokine Production Against Triple Negative Breast Cancer Cells. Juliá EP, Amante A, Pampena MB, Mordoh J, Levy EM. Front Immunol. 2018 Sep 20;9:2140. doi: 10.3389/fimmu.2018.02140. eCollection 2018.
  • High neutrophil to lymphocyte ratio and decreased CD69+NK cells represent a phenotype of high risk in early-stage breast cancer patients. Mandó P, Rizzo M, Roberti MP, Juliá EP, Pampena MB, Pérez de la Puente C, Loza CM, Ponce C, Nadal J, Coló FA, Mordoh J, Levy EM.Onco Targets Ther. 2018 May 17;11:2901-2910. doi: 10.2147/OTT.S160911. eCollection 2018.
  • Changes in the TCRβ Repertoire and Tumor Immune Signature From a Cutaneous Melanoma Patient Immunized With the CSF-470 Vaccine: A Case Report. Aris M, Bravo AI, Pampena MB, Blanco PA, Carri I, Koile D, Yankilevich P, Levy EM, Barrio MM, Mordoh J. Front Immunol. 2018 May 3;9:955. doi: 10.3389/fimmu.2018.00955. eCollection 2018.
  • Evaluation of the primitive fraction by functional in vitro assays at the RNA and DNA level represents a novel tool for complementing molecular monitoring in chronic myeloid leukemia. Ruiz MS, Sanchez MB, Gutiérrez L, Koile D, Yankilevich P, Mosqueira C, Cranco S, Custidiano MDR, Freitas J, Foncuberta C, Moiraghi B, Pavlovsky C, Pérez MA, Ventriglia V, Ávalos JS, Mordoh J, Larripa I, Bianchini M. Oncotarget. 2018 Apr 17;9(29):20255-20264. doi: 10.18632/oncotarget.24749. eCollection 2018 Apr 17.
  • Early Events of the Reaction Elicited by CSF-470 Melanoma Vaccine Plus Adjuvants: An In Vitro Analysis of Immune Recruitment and Cytokine Release. Pampena MB, Barrio MM, Juliá EP, Blanco PA, vonEuw EM, Mordoh J, Levy EM. Front Immunol. 2017 Oct 23;8:1342. doi: 10.3389/fimmu.2017.01342. eCollection 2017.
  • Immunomodulatory Monoclonal Antibodies in Combined Immunotherapy Trials for Cutaneous Melanoma. Aris M, Mordoh J, Barrio MM.Front Immunol. 2017 Aug 25;8:1024. doi: 10.3389/fimmu.2017.01024. eCollection 2017.
  • Phase II Study of Adjuvant Immunotherapy with the CSF-470 Vaccine Plus Bacillus Calmette-Guerin Plus Recombinant Human Granulocyte Macrophage-Colony Stimulating Factor vs Medium-Dose Interferon Alpha 2B in Stages IIB, IIC, and III Cutaneous Melanoma Patients: A Single Institution, Randomized Study. Mordoh J, Pampena MB, Aris M, Blanco PA, Lombardo M, von Euw EM, Mac Keon S, Yépez Crow M, Bravo AI, O’Connor JM, Orlando AG, Ramello F, Levy EM, Barrio MM.Front Immunol. 2017 May 31;8:625. doi: 10.3389/fimmu.2017.00625. eCollection 2017.
  • Metallothionein 1G promotes the differentiation of HT-29 human colorectal cancer cells. Arriaga JM, Bravo AI, Mordoh J, Bianchini M.Oncol Rep. 2017 May;37(5):2633-2651. doi: 10.3892/or.2017.5547. Epub 2017 Apr 3.
  • In vitro long-term treatment with MAPK inhibitors induces melanoma cells with resistance plasticity to inhibitors while retaining sensitivity to CD8 T cells. MadorskyRowdo FP, Barón A, von Euw EM, Mordoh J. Oncol Rep. 2017 Mar;37(3):1367-1378. doi: 10.3892/or.2017.5363. Epub 2017 Jan 13.
  • Standardization of molecular monitoring for chronic myeloid leukemia in Latin America using locally produced secondary cellular calibrators. Ruiz MS, Medina M, Tapia I, Mordoh J, Cross NC, Larripa I, Bianchini M. Leukemia. 2016 Nov;30(11):2258-2260. doi: 10.1038/leu.2016.197. Epub 2016 Jul 25.
  • Phenotypic and Functional Dysregulated Blood NK Cells in Colorectal Cancer Patients Can Be Activated by Cetuximab Plus IL-2 or IL-15. Rocca YS, Roberti MP, Juliá EP, Pampena MB, Bruno L, Rivero S, Huertas E, Sánchez Loria F, Pairola A, Caignard A, Mordoh J, Levy EM. Front Immunol. 2016 Oct 10;7:413. eCollection 2016.
  • Editorial: “Cancer Immunotherapy: Lights and Shadows”. Barrio MM, Levy EM, Mordoh J. Front Immunol. 2015 Jul 7;6:350. doi: 10.3389/fimmu.2015.00350. eCollection 2015.
  • Cytokine-enhanced maturation and migration to the lymph nodes of a human dying melanoma cell-loaded dendritic cell vaccine. Pizzurro GA, Tapia IJ, Sganga L, Podhajcer OL, Mordoh J, Barrio MM. Cancer Immunol Immunother. 2015 Nov;64(11):1393-406. doi: 10.1007/s00262-015-1743-z. Epub 2015 Jul 22.
  • Inoculation site from a cutaneous melanoma patient treated with an allogeneic therapeutic vaccine: a case report. Aris M, Bravo AI, Barrio MM, Mordoh J. Front Immunol. 2015 Mar 30;6:144. doi: 10.3389/fimmu.2015.00144. eCollection 2015.
  • Immunotherapy in Cancer: A Combat between Tumors and the Immune System; You Win Some, You Lose Some. MadorskyRowdo FP, Baron A, Urrutia M, Mordoh J. Front Immunol. 2015 Mar 26;6:127. doi: 10.3389/fimmu.2015.00127. eCollection 2015.
  • Overexpression of CD85j in TNBC patients inhibits Cetuximab-mediated NK-cell ADCC but can be restored with CD85j functional blockade. Roberti MP, Juliá EP, Rocca YS, Amat M, Bravo AI, Loza J, Coló F, Loza CM, Fabiano V, Maino M, Podhorzer A, Fainboim L, Barrio MM, Mordoh J, Levy EM. Eur J Immunol. 2015 May;45(5):1560-9. doi: 10.1002/eji.201445353. Epub 2015 Apr 7.
  • Combining immunotherapy with oncogene-targeted therapy: a new road for melanoma treatment, Mariana Aris, María Marcela Barrio. Frontiers in Immunology doi: 10.3389/fimmu.2015.00046
  • Chemokine receptor specific antibodies in cancer immunotherapy: achievements and challenges. Maria Vela, Mariana Aris, Mercedes Llorente, Jose A. Garcia-Sanz and Leonor Kremer. Frontiers in Immunology, doi: 10.3389/fimmu.2015.00012